Overall, PRL3 was detected in 4 of 8 (50%) initial diagnostic biopsy samples and 6 of 8 (75%) relapsed tumor samples, suggesting that PRL3 overexpression is more frequently present in relapse samples than diagnostic samples (Figure 3A). Here, PTP4A3 is linked to neoplasm.